Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD.
Vilorio-Marqués L, Castañón Fernández C, Mora E, Gutiérrez L, Rey Bua B, Jiménez Lorenzo MJ, Díaz Beya M, Vara Pampliega M, Molero A, Sánchez-García J, Calabuig M, Cedena MT, Chen-Liang T, Díaz Santa JA, Padilla I, Hernández F, Díez R, Asensi P, Xicoy B, Sanz G, Valcárcel D, Diez-Campelo M, Bernal T. Vilorio-Marqués L, et al. Among authors: bernal t. Ther Adv Hematol. 2022 Sep 29;13:20406207221127547. doi: 10.1177/20406207221127547. eCollection 2022. Ther Adv Hematol. 2022. PMID: 36199837 Free PMC article.
Cytogenetic risk stratification in chronic myelomonocytic leukemia.
Such E, Cervera J, Costa D, Solé F, Vallespí T, Luño E, Collado R, Calasanz MJ, Hernández-Rivas JM, Cigudosa JC, Nomdedeu B, Mallo M, Carbonell F, Bueno J, Ardanaz MT, Ramos F, Tormo M, Sancho-Tello R, del Cañizo C, Gómez V, Marco V, Xicoy B, Bonanad S, Pedro C, Bernal T, Sanz GF. Such E, et al. Among authors: bernal t. Haematologica. 2011 Mar;96(3):375-83. doi: 10.3324/haematol.2010.030957. Epub 2010 Nov 25. Haematologica. 2011. PMID: 21109693 Free PMC article.
Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.
Xicoy B, Jiménez MJ, García O, Bargay J, Martínez-Robles V, Brunet S, Arilla MJ, Pérez de Oteyza J, Andreu R, Casaño FJ, Cervero CJ, Bailén A, Díez M, González B, Vicente AI, Pedro C, Bernal T, Luño E, Cedena MT, Palomera L, Simiele A, Calvo JM, Marco V, Gómez E, Gómez M, Gallardo D, Muñoz J, de Paz R, Grau J, Ribera JM, Benlloch LE, Sanz G. Xicoy B, et al. Among authors: bernal t. Leuk Lymphoma. 2014 Jun;55(6):1300-3. doi: 10.3109/10428194.2013.834532. Epub 2013 Sep 16. Leuk Lymphoma. 2014. PMID: 23952246
Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.
Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, González M, Vidriales B, Sánchez-Guijo FM, López-Corral L, Luño E, del Cañizo C. Bernal T, et al. Leuk Res. 2014 May;38(5):551-6. doi: 10.1016/j.leukres.2014.02.001. Epub 2014 Feb 10. Leuk Res. 2014. PMID: 24655806
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
Falantes J, Delgado RG, Calderón-Cabrera C, Márquez-Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF, Bonanad S, Pérez-Simón JA, Sanz G; Spanish Group of Myelodysplastic Syndromes (GESMD). Falantes J, et al. Among authors: bernal t. Leuk Res. 2015 Jan;39(1):52-7. doi: 10.1016/j.leukres.2014.10.004. Epub 2014 Oct 30. Leuk Res. 2015. PMID: 25487012 Clinical Trial.
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.
Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G. Xicoy B, et al. Among authors: bernal t. Eur J Haematol. 2016 Jul;97(1):33-8. doi: 10.1111/ejh.12679. Epub 2015 Oct 22. Eur J Haematol. 2016. PMID: 26341961
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P. Park S, et al. Among authors: bernal t. J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28. J Clin Oncol. 2017. PMID: 28350519 Free article.
The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS.
Xicoy B, Triguero A, Such E, García O, Jiménez MJ, Arnán M, Bernal T, Diaz-Beya M, Valcárcel D, Pedro C, Ramos F, Amigo ML, Collado R, Palomo L, Ardanaz MT, Cedena MT, Grau J, Zamora L, Sanz G. Xicoy B, et al. Among authors: bernal t. Leuk Res. 2018 Jul;70:34-36. doi: 10.1016/j.leukres.2018.05.003. Epub 2018 May 9. Leuk Res. 2018. PMID: 29775844 No abstract available.
The Value of Adding Surveillance Cultures to Fluoroquinolone Prophylaxis in the Management of Multiresistant Gram Negative Bacterial Infections in Acute Myeloid Leukemia.
Castañón C, Fernández Moreno A, Fernández Verdugo AM, Fernández J, Martínez Ortega C, Alaguero M, Nicolás C, Vilorio Marqués L, Bernal T. Castañón C, et al. Among authors: bernal t. J Clin Med. 2019 Nov 15;8(11):1985. doi: 10.3390/jcm8111985. J Clin Med. 2019. PMID: 31731650 Free PMC article.
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K, Izquierdo MM, Cadenas FL, Ramos F, Sánchez JMH, Lumbreras E, Robledo C, Del Real JS, Caballero JC, Collado R, Bernal T, Pedro C, Insunza A, de Paz R, Xicoy B, Salido E, García JS, Mínguez SS, García CM, Muñoz AMS, Barba MS, Rivas JMH, Abáigar M, Campelo MD. Janusz K, et al. Among authors: bernal t. Ann Hematol. 2021 Aug;100(8):1995-2004. doi: 10.1007/s00277-020-04360-4. Epub 2021 Jan 6. Ann Hematol. 2021. PMID: 33409621
108 results